December 23, 2020
How Does Altis Biosystems Envision the Future of the Pharma/Biopharma Industry?
There is a growing need to address the high failure rate of drug candidates as they progress through clinical trials. Altis Biosystems aims to bring its technological advances to the forefront, enabling the drug development process to more effectively translate results from preclinical experiments to late-stage clinical trials.
November 30, 2020
Enhancing Human Gut Tissue Models through Gene Editing
The variety of normal and diseased human tissues needed to perform comprehensive screening of drug candidates is a key resource for next-generation preclinical models, but obtaining these tissues is challenging. Gene editing enables Altis Biosystems to offer a diverse array of RepliGut® human gut models tailored for specific research programs.
November 20, 2020
A Gut Feeling About the Future of Healthcare
Scott Magness, Chief Scientific Officer at Altis Biosystems, discusses the impact that RepliGut®—a human stem cell-derived platform that recreates the intestinal epithelium—may have on stem cell research and drug testing.
November 10, 2020
Increasing the Efficiency of Drug Development With Preclinical Testing Using Human Intestinal Stem Cells
Due to a lack of robust in vivo gut models, animal studies are generally required to evaluate gut toxicity. However, these studies can be lengthy and expensive and may not accurately recapitulate the behavior of the human gastrointestinal tract. Drugs are thus often developed with undesired gut side effects that are not apparent until clinical trials.
October 23, 2020
Characterization of a Novel Human Primary Intestinal Epithelial Monolayer Platform in Response to Cytokine Challenge (Poster)
The ability to grow and expend primary human epithelial cells in vitro has been a significant advancement in the field of gastrointestinal biology. The ALTIS RepliGut® Planar system uses a proprietary biomimetic scaffold on a porous membrane to form a human intestinal epithelial monolayer...